Squarepoint’s Eikon Therapeutics EIKN Stock Holding History

Squarepoint’s Portfolio EIKN Stock Details EIKN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-30,978	Closed	-$328K	–	5134
2026 Q1	$328K	Buy	+30,978	New	+$414K	﹤0.01%	3641

Other funds holding EIKN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

FCMV

Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Squarepoint's EIKN Position: Q2 2026 in Review

Squarepoint sold out of Eikon Therapeutics (EIKN) in Q2 2026, closing a stake of 30,978 shares — an estimated $328K sold.

Squarepoint first reported a position in EIKN in Q1 2026 and held it in 1 quarter. The position peaked at $328K in Q1 2026. 70 funds tracked by Wall St. Rank hold EIKN as of Q2 2026.

Squarepoint reported no remaining Eikon Therapeutics position as of Q2 2026 after selling out during the quarter.
Squarepoint sold 30,978 Eikon Therapeutics shares in Q2 2026, an estimated $328K.
Squarepoint first reported a position in Eikon Therapeutics in Q1 2026 and held it in 1 quarter.
Squarepoint's Eikon Therapeutics position peaked at $328K in Q1 2026.
70 funds tracked by Wall St. Rank held Eikon Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.